FDA Recall: Vitruvias Therapeutics Thyroid Tablets, USP 30
Source: FDA
File Your Claim Now

FDA Recall: Vitruvias Therapeutics Thyroid Tablets, USP 30

Vitruvias Therapeutics • August 24, 2026

Vitruvias Therapeutics Thyroid Tablets 30 mg Recall: FDA Warns of Superpotency Risk

Vitruvias Therapeutics, Inc. has issued a nationwide recall of one lot of Thyroid Tablets, USP 30 mg after quality testing showed the tablets may contain higher-than-approved levels of thyroid hormone (superpotency). Consuming super-potent tablets can trigger hyperthyroidism. If you have this medicine, verify the lot number, stop using it, and contact your prescriber.

Recall Fast Facts

  • Product: Thyroid Tablets, USP 30 mg
  • Manufacturer: Vitruvias Therapeutics, Inc.
  • Affected Lot: 504950  |  Expiration: 09/30/2026
  • NDC: 69680-166-00
  • Distribution Window: Jan 31 2025 – Sep 30 2025 (United States)
  • Reason for Recall: Superpotent tablets may induce hyperthyroidism

Official Source

Health Risks of Super-Potent Thyroid Medication

Excess thyroid hormone can lead to the following hyperthyroidism symptoms:

  • Unintentional weight loss, heat intolerance, anxiety, tremor
  • Muscle weakness, high blood pressure, chest discomfort
  • Tachycardia or abnormal heart rhythms

Older adults, pregnant patients, and infants are especially vulnerable to severe outcomes such as cardiac crises, premature delivery, or impaired growth and development.

Step-by-Step Guidance for Consumers

  1. Check your prescription bottle. If the lot number reads 504950, discontinue use.
  2. Do not stop thyroid therapy abruptly; call your healthcare provider for a replacement prescription.
  3. Follow disposal instructions from your pharmacist or local take-back program.
  4. Report any side effects to FDA MedWatch online or by calling 1-800-332-1088.

Company & FDA Contact Information

Questions about the recall? Contact Vitruvias Therapeutics Monday–Friday, 9 a.m.–5 p.m. CT:

Adverse events can be reported to the FDA’s MedWatch program online.

Recall Images

Package label for Vitruvias Thyroid Tablets USP 30 mg, Lot 504950
Source: FDA

Frequently Asked Questions

1. What specific Vitruvias Therapeutics Thyroid Tablets are recalled?
The recall affects only Thyroid Tablets, USP 30 mg from Lot 504950 (NDC 69680-166-00) with an expiration date of 09/30/2026.
2. Where can I find the Lot 504950 number on my Vitruvias Thyroid Tablets?
The lot number appears on both the pharmacy dispensing label and the manufacturer’s bottle label, usually printed near the expiration date.
3. Should I stop taking Vitruvias Therapeutics Thyroid Tablets immediately?
Discontinue tablets from Lot 504950, but consult your prescriber promptly to avoid interruption in thyroid therapy.
4. Will I receive a refund or free replacement for the recalled Vitruvias Thyroid Tablets?
Most pharmacies will provide a replacement prescription at no additional cost. Vitruvias has instructed wholesalers to destroy returned product.
5. What symptoms signal hyperthyroidism from super-potent Vitruvias Thyroid Tablets?
Watch for rapid heartbeat, unexplained weight loss, sweating, nervousness, or muscle weakness and seek medical attention if they occur.
6. How do I report side effects from Vitruvias Therapeutics Thyroid Tablets Lot 504950?
Submit a report through the FDA MedWatch portal or call 1-800-332-1088. Include the lot number and describe your symptoms.

Content current as of: 08/24/2026. This article is for informational purposes only and is not a substitute for professional medical advice.

File Your Claim Now